Disfiguring Annular Sarcoidosis Improved by Adalimumab
Depending on the location, dermatoses can produce blemishes that severely impair quality of life and require highly effective treatment that is otherwise used for extensive skin involvement. We report the case of a 39-year-old, otherwise healthy male disfigured by an 8 × 7-cm hypopigmented and centr...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2011-05-01
|
Series: | Case Reports in Dermatology |
Subjects: | |
Online Access: | http://www.karger.com/Article/FullText/328796 |
id |
doaj-8fac076639f143ad95425d1b4265ff24 |
---|---|
record_format |
Article |
spelling |
doaj-8fac076639f143ad95425d1b4265ff242020-11-25T01:08:27ZengKarger PublishersCase Reports in Dermatology1662-65672011-05-013210310610.1159/000328796328796Disfiguring Annular Sarcoidosis Improved by AdalimumabC.A. KaiserA. CozzioG.F.L. HofbauerJ. KamarashevL.E. FrenchA.A. NavariniDepending on the location, dermatoses can produce blemishes that severely impair quality of life and require highly effective treatment that is otherwise used for extensive skin involvement. We report the case of a 39-year-old, otherwise healthy male disfigured by an 8 × 7-cm hypopigmented and centrally atrophic annular plaque with erythematous indurated borders in an area of scar tissue on his forehead. Skin biopsies revealed non-caseating granulomas, and hilar involvement was identified, leading to the diagnosis of systemic sarcoidosis stage II with cutaneous involvement. The lesions proved resistant to multiple therapies, but responded within 4 months to adalimumab with regression of the lesion and inflammatory infiltrate. The visual analogue scale of disease activity decreased from 7/10 to 3.5/10, and the Dermatology Life Quality Index from 16/30 to 3/30 points. In conclusion, TNF-α inhibition can control inflammation and disfigurement by cutaneous sarcoidosis and restore quality of life.http://www.karger.com/Article/FullText/328796Systemic sarcoidosisCutaneous sarcoidosisSarcoidosis treatmentAdalimumabTNF-α antagonist |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
C.A. Kaiser A. Cozzio G.F.L. Hofbauer J. Kamarashev L.E. French A.A. Navarini |
spellingShingle |
C.A. Kaiser A. Cozzio G.F.L. Hofbauer J. Kamarashev L.E. French A.A. Navarini Disfiguring Annular Sarcoidosis Improved by Adalimumab Case Reports in Dermatology Systemic sarcoidosis Cutaneous sarcoidosis Sarcoidosis treatment Adalimumab TNF-α antagonist |
author_facet |
C.A. Kaiser A. Cozzio G.F.L. Hofbauer J. Kamarashev L.E. French A.A. Navarini |
author_sort |
C.A. Kaiser |
title |
Disfiguring Annular Sarcoidosis Improved by Adalimumab |
title_short |
Disfiguring Annular Sarcoidosis Improved by Adalimumab |
title_full |
Disfiguring Annular Sarcoidosis Improved by Adalimumab |
title_fullStr |
Disfiguring Annular Sarcoidosis Improved by Adalimumab |
title_full_unstemmed |
Disfiguring Annular Sarcoidosis Improved by Adalimumab |
title_sort |
disfiguring annular sarcoidosis improved by adalimumab |
publisher |
Karger Publishers |
series |
Case Reports in Dermatology |
issn |
1662-6567 |
publishDate |
2011-05-01 |
description |
Depending on the location, dermatoses can produce blemishes that severely impair quality of life and require highly effective treatment that is otherwise used for extensive skin involvement. We report the case of a 39-year-old, otherwise healthy male disfigured by an 8 × 7-cm hypopigmented and centrally atrophic annular plaque with erythematous indurated borders in an area of scar tissue on his forehead. Skin biopsies revealed non-caseating granulomas, and hilar involvement was identified, leading to the diagnosis of systemic sarcoidosis stage II with cutaneous involvement. The lesions proved resistant to multiple therapies, but responded within 4 months to adalimumab with regression of the lesion and inflammatory infiltrate. The visual analogue scale of disease activity decreased from 7/10 to 3.5/10, and the Dermatology Life Quality Index from 16/30 to 3/30 points. In conclusion, TNF-α inhibition can control inflammation and disfigurement by cutaneous sarcoidosis and restore quality of life. |
topic |
Systemic sarcoidosis Cutaneous sarcoidosis Sarcoidosis treatment Adalimumab TNF-α antagonist |
url |
http://www.karger.com/Article/FullText/328796 |
work_keys_str_mv |
AT cakaiser disfiguringannularsarcoidosisimprovedbyadalimumab AT acozzio disfiguringannularsarcoidosisimprovedbyadalimumab AT gflhofbauer disfiguringannularsarcoidosisimprovedbyadalimumab AT jkamarashev disfiguringannularsarcoidosisimprovedbyadalimumab AT lefrench disfiguringannularsarcoidosisimprovedbyadalimumab AT aanavarini disfiguringannularsarcoidosisimprovedbyadalimumab |
_version_ |
1725182479814361088 |